Hematologic Oncology

Eunice S. Wang, MD, discusses the role of menin inhibitors like revumenib in AML with KMT2A rearrangements or NPM1 mutations.

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

The FDA granted fast track designation azercabtagene zapreleucel for relapsed/refractory diffuse large B-cell lymphoma.

Bexobrutideg received orphan drug designation from the FDA for the treatment of patients with Waldenström macroglobulinemia.

Orca-T led to an improvement in chronic graft-vs-host disease–free survival in patients with advanced hematologic malignancies.

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

The γδ T-cell agent INB-100 demonstrated a 100% relapse-free survival rate in patients with AML.

Cema-cel generated CRs, most of which were durable, among patients with relapsed/refractory LBCL who were naive to anti-CD19 CAR T-cell therapy.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

First-line olverembatinib plus low-intensity chemotherapy has received breakthrough therapy designation in China for patients with Ph-positive ALL.

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.